Search results for: Market Access
Filter search results
How Should the World Pay for a COVID-19 Vaccine?
31 July 2020
…(2020) Blueprint for a Market-Driven value-based advance commitment (MVAC) for tuberculosis. Center for Global Development and the Office of Health Economics. Available: https://www.cgdev.org/publication/blueprint-market-driven-value-based-advance-commitment-tuberculosis Chalkidou K, Towse A, Silverman R, et…
The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
1 January 2011
This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development of the health…
Biosimilars: Issues Overview
1 June 2010
…and makes unlikely the aggressive price competition on entry that has characterised the generics market. Overall, the number of biologics that have a large enough market share to attract biosimilars is…
The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?
25 June 2020
…best chances of securing safe and effective vaccines we need a payment mechanism using an Advance Market Commitment (AMC). He proposes a Benefit Based Advance Market Commitment (BBAMC). Crucially, this…
OHE’s AMR consultation response
21 November 2023
…products receiving a marketing authorisation in the period since the previous tender will be able to apply, as will products with a high probability of receiving a marketing authorisation within…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
…differences mean that biosimilar markets will evolve in a more complex way than traditional, small molecule, chemical generics markets. Regulators will need clinical trial evidence of efficacy and safety before…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Adrian presented a paper examining the role of health technology assessment (HTA) (slides below). Placing the Evolution of HTA In Emerging Markets in Context of Health System Development from Office…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
…through clinical trials and to market. To drive the necessary investment, BRICS need to send a clear signal to the market that they are willing to pay for innovations that…
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
17 February 2015
…research. More generally, finding better mechanisms to enable differential pricing between and within LMICs is an important challenge for firms and policymakers. Access the full paper (open access) here….